Cardiovascular Registry of Atrial Fibrillation

Brazilian Clinical Research Institute2,016 enrolled

Overview

Follow a representative sample of Latin American patients diagnosed with atrial fibrillation to set data on demographic characteristics, documenting antithrombotic therapy, describe the INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke, hemorrhage and death

Patients will be followed 6 months and 1 year after the baseline visit and will be collected data of antithrombotic therapy, laboratory data, discontinuation rates of antithrombotic therapy and clinical outcomes.

Study Type

OBSERVATIONAL

Enrollment

2,016

Conditions

Atrial Fibrillation Atrial Flutter

Interventions

Patient Registry DataOTHER

To set data on demographic characteristics,documenting antithrombotic therapy, describe the INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke, hemorrhage and death.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \> 18 years-old that signed informed consent; * Atrial Fibrillation or Atrial Flutter at the time of inclusion documented in source document; * If the patient is not in atrial fibrillation or Atrial Flutter rhythm, s/he should have 2 electrographic records, at least 15 days apart between them, with one of them being performed within the last 6 months before enrollment (AF may be documented by 12-lead ECG, Holter monitor-24h); Exclusion Criteria: * Patients who did not agree to participate. * Patients without possibility of monitoring for one year.

Locations (17)

Hospital Interzonal General de Agudos "Dr. José Penna"

Bahía Blanca, Buenos Aires, Argentina

DIM Clínica Privada

Ramos Mejía, Buenos Aires, Argentina

Outcomes

Primary Outcomes

INR control rate

Time frame: 12 months

Oral anticoagulation discontinuation rate

Time frame: 12 months

Percentage of death

Time frame: 12 months

Percentage of stroke

Time frame: 12 months

Percentage of systemic embolism

Time frame: 12 months

Percentage of myocardial infarction

Time frame: 12 months

Percentage of major bleeding

Time frame: 12 months

Percentage of electrical cardioversion

Time frame: 12 months

Percentage of percutaneous ablation of AF

Time frame: 12 months

Percentage of atrioventricular junction ablation

Time frame: 12 months

Percentage of patients that need of pacemaker implantation

Time frame: 12 monts

Percentage of other cardiovascular hospitalization

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.